Research Synthesis: Semaglutide Adverse Safety — full paper

Researka accepted publication: 060fa963-9582-4658-ad87-91a057301d4f Source submission: 807814a9-fc08-449b-8a72-18e47e815d0d This paper synthesizes evidence on semaglutide adverse safety across 15 accepted source papers and 1436 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 13 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 27 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the safety and comorbidity, cardiometabolic outcome classes, null signals in the dosing and pharmacokinetics, safety and comorbidity outcome classes, and negative signals in the safety and comorbidity outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that semaglutide adverse safety remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.